Acadia Pharmaceuticals
Our history is rooted in groundbreaking science. From developing the first and only treatment for hallucinations and delusions in Parkinson’s disease psychosis to commercializing the first therapy for Rett syndrome, Acadia has consistently advanced care where it is most needed. Today, with a proven commercial portfolio and a diverse pipeline, we are poised to lead the next era of therapeutic innovation in neurological disorders and rare diseases.
Driven by urgency and the reality that too many patients have few or no treatment options, we are committed to advancing where others hesitate.
Bringing Innovative Treatments to Patients
Inspired by the patients and families who count on us, Acadians across North America, Europe, and beyond dedicate their work to advancing therapies in underserved neurological disorders and rare diseases. Their collective expertise drives innovations that bring meaningful moments and brighter futures to patients and loved ones around the world.